Europe
Apogenix announced that it will present updates on its three most advanced HERA-ligands as well as lead drug candidate asunercept at four upcoming international conferences.
Full data will be shared at a later conference, but the study marked the first time a BTK inhibitor showed benefit as a monotherapy in CLL.
On March 27, the U.S. Food and Drug Administration (FDA) approved Novartis’ Mayzent (isiponimod) for adults with relapsing types of multiple sclerosis.
GW Pharmaceuticals anticipates filing a supplemental New Drug Application with the FDA for the new indication later this year.
New strategies urgently needed to prevent tumors from evading the immune system and to make them more susceptible to attack by immune cells
Sales estimated to double in 2019 and exceed EUR 50 million
Adrenomed AG, the vascular integrity company, announced its participation at three upcoming conferences in Europe and the USA.
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
With a $250 million cash down payment, Denmark’s H. Lundbeck A/S snapped up San Diego-based Abide Therapeutics to gain a novel discovery platform and a U.S.-based research hub.
NOXXON Pharma N.V. announced the appointment of Dr. Maurizio PetitBon, member of the Supervisory Board since September 2016, as Chairman of NOXXON’s Board.
PRESS RELEASES